

## Steps before prequalification

### I. BACKGROUND INFORMATION ON THE PROCEDURE

#### 1. Submission of the dossier

The company PANPHARMA, submitted in 2021 an application for Oxytocin 10 IU/ml concentrate for solution for infusion\* (RH097) to be assessed with the aim of including Oxytocin 10 IU/ml concentrate for solution for infusion in the list of prequalified medicinal products for reproductive health conditions in women.

Oxytocin 10 IU/ml concentrate for solution for infusion was assessed according to the ‘*Procedure for Assessing the Acceptability, in Principle, of Pharmaceutical Products for Purchase by United Nations Agencies*’ by the team of WHO assessors. The assessors are senior experts, mainly from national authorities, invited by WHO to participate in the prequalification assessment process.

#### 2. Steps taken in the evaluation of the product

May 2021	During the meeting of the assessment team the quality data were reviewed and further information was requested.
June 2021	The applicant’s response letter was received.
June 2021	The quality data were reviewed and found to comply with the relevant WHO requirements
01 July 2021	Oxytocin 10 IU/ml concentrate for solution for infusion was included in the list of prequalified medicinal products.

Further information is available at:

<https://extranet.who.int/pqweb/medicines/prequalified-lists/finished-pharmaceutical-products>

---

\* Trade names are not prequalified by WHO. This is the National Medicines Regulatory Authority’s responsibility Throughout this WHOPAR the proprietary name is given as an example only.